Mathew Aby J.'s Form 4 filing
Biolife Solutions Inc (BLFS) · filed Dec 4, 2023
- Accession no.
- 0001628280-23-040675
- Filed
- Dec 4, 2023
- Trade date
- Nov 19-Dec 1, 2023
- Filing delay
- 15 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $7.31K. It was filed 15 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mathew Aby J.CIK 0001556355 | Officer (EVP & Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2023 | Common Stock | AGrant or awardAcquired | +826 | –F1 | – | 276,552 | Direct | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −591 | $12.37 | −$7,310.67 | 275,961 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.
Referenced by the price of 1 transaction in Table I.